Vicore Pharma (VICO) Company presentation summary

Strategic vision and financial position

• Aims to transform patient outcomes by targeting the AT2 receptor to halt and reverse disease pathology, focusing on rare lung diseases.

• Operates from Stockholm, Cambridge (MA), and Copenhagen, and is publicly listed on Nasdaq Stockholm.

• Holds a market cap of $381 million and a pro forma financial position of $137 million as of early 2026.

• Supported by leading specialist investors in the US and Europe.

Lead program and clinical pipeline

• Buloxibutid, a first-in-class oral AT2 receptor agonist, is in a global Phase 2b trial (ASPIRE) for idiopathic pulmonary fibrosis (IPF), with Orphan Drug and Fast Track designations from the FDA.

• The ASPIRE trial targets full enrollment by H1 2026 and includes global ex-Japan rights, with a partnership in Japan.

• Additional ATRAGS compounds are in preclinical development for multiple indications.

Market opportunity and unmet need

• IPF is a progressive, fatal disease with a 5-year mortality rate of 80% and significant unmet need despite three FDA-approved therapies.

• The global IPF market is projected to grow from $4.2B in 2024 to over $10B by 2030-2033, driven by new approvals, increased awareness, and rising prevalence.

• Existing therapies offer only modest slowing of disease progression and have tolerability issues, highlighting the need for innovative treatments.